Transcatheter arterial chemoembolization (TACE) is an effective therapy for hepatocellular
carcinoma (HCC). However, acute kidney injury (AKI) may occur after TACE due to the contrast agent
and cytotoxic anticancer drugs used in this procedure. Post-TACE AKI is not an unusual event, and
may adversely affect patient outcome. Coexisting situations including cirrhosis, renal insufficiency,
diabetes and hypertension play a role in the development of HCC, and may predispose patients to AKI
after TACE. Most post-TACE are transient and reversible, while prolonged AKI may predict a decreased
survival. The best strategy to manage post-TACE AKI is prevention. Patients, before undergoing
TACE, should be carefully assessed. In this study, we reviewed the current literature published in
English about the incidence rate, risk factors, management and prognosis of AKI in patients with HCC
undergoing TACE for a better understanding of this complication.
Keywords: Acute kidney injury, transcatheter arterial chemoembolization, incidence, risk factor, prognosis, prevention.
Rights & PermissionsPrintExport